Evaxion Biotech A/SEVAX
13F holders, Q1 2025 (March 31)2holders −7
0new positions
7sold out
$1.85avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Evaxion Biotech A/S (EVAX) in their 13F filings, down 7 from Q4 2024. 0 opened new positions and 7 sold out. The largest holders were Merck & Co., Inc. ($2.2M) and Rhumbline Advisers ($3).
- Company
- Evaxion Biotech A/S
- CUSIP
- 29970R204
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 7 | $223K |
All 13F filers, Q4 2024 → Q1 2025: 671,847 shares bought and 264,202 shares sold, net +407,645 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Merck & Co., Inc. | 1.37% | Add +123.9% | 1,214,126 | $2.2M |
| Rhumbline Advisers | 0.00% | Reduce -99.3% | 2 | $3 |
"% of holder's portfolio" is EVAX's weight in each manager's 13F, not the share of Evaxion Biotech A/S the manager owns.